ELIONOVA, Haute école d’ingénierie et d’architecture and University of Fribourg, receive 480k CHF funding from Innosuisse, the Swiss Innovation Agency for a joint project to develop a comprehensive blood test for sepsis.

With a significant contribution for the development in the Medtech industry, Haute école d’ingénierie et d’architecture and University of Fribourg together with  ELIONOVA as an implementation partner have received a substantial grant of CHF 480’000 for the Research Partners. Innosuisse supports SMEs, startups and other Swiss organizations in their R&D activities. With the acquired funding, ELIONOVA continues the development of its EVA technology and aims to expand its technology into further markets. In emergency medicine, Elionova's high precision diagnostic technology at the point-of-care improves early detection of septic patients, a key to more efficient treatment and to an improvement of outcomes.